US Tariffs on Generic Drugs: India's Pharma Exporters Face Challenge, Cost Advantage May Help
US President Donald Trump's proposed tariffs of up to 200% on imported generic medicines could pressure Indian pharmaceutical exporters, but India's cost advantage may help many drugs remain competitive in the US market, according to the Global Trade Research Initiative (GTRI).













